On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...

Merck stock could take another hit Thursday after the company reported another quarter of light sales for its HPV vaccine, ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

Merck & Co. Inc. managers escaped allegations that they hurt the pharmaceutical giant by misleading investors over traction ...

While Secretary Kennedy frets over food dye in Froot Loops, his 2023 attack on Gardasil — a vaccine proven to prevent deadly ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

Read about Merck, EssilorLuxottica, Wuxi Biologics and more in the latest Market Talks covering the Health Care sector.

For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share ...

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.